Standards of medical care in diabetes. VI. Prevention and management of diabetes complications.

GUIDELINE TITLE
Standards of medical care in diabetes. VI. Prevention and management of diabetes complications.

BIBLIOGRAPHIC SOURCE(S)
American Diabetes Association (ADA). Standards of medical care in diabetes. VI. Prevention and management of diabetes complications. Diabetes Care 2010 Jan;33(Suppl 1):S29-39.

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: American Diabetes Association (ADA). Standards of medical care in diabetes. VI. Prevention and management of diabetes complications. Diabetes Care 2008 Jan;31(Suppl 1):S24-33.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

November 17, 2009 - Plavix (clopidogrel): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of new safety information concerning an interaction between clopidogrel (Plavix) and omeprazole (Prilosec/Prilosec OTC) used to reduce stomach acid. New data show that when clopidogrel and omeprazole are taken together, the effectiveness of clopidogrel is reduced.

open here to see the full-text:
Standards of medical care in diabetes. VI. Prevention and management of diabetes complications.